150,000 Shares in LifeMD, Inc. $LFMD Bought by MYDA Advisors LLC

MYDA Advisors LLC bought a new position in LifeMD, Inc. (NASDAQ:LFMD) during the fourth quarter, Holdings Channel reports. The fund bought 150,000 shares of the company’s stock, valued at approximately $512,000.

A number of other hedge funds have also modified their holdings of LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after acquiring an additional 2,235 shares during the last quarter. Creative Planning acquired a new position in shares of LifeMD in the 2nd quarter worth $272,000. JPMorgan Chase & Co. grew its holdings in shares of LifeMD by 581.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after acquiring an additional 352,004 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of LifeMD by 187.4% in the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after acquiring an additional 6,614 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of LifeMD by 8.7% in the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after acquiring an additional 4,281 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on LFMD. Loop Capital set a $10.00 target price on LifeMD in a report on Thursday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research report on Tuesday, May 26th. Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Finally, Mizuho raised LifeMD from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $6.00 to $8.00 in a research report on Monday, March 16th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Price Performance

Shares of LifeMD stock opened at $4.70 on Monday. The stock has a market cap of $227.29 million, a PE ratio of 94.02 and a beta of 1.98. The business has a fifty day simple moving average of $4.36 and a 200-day simple moving average of $3.80. LifeMD, Inc. has a 12 month low of $2.56 and a 12 month high of $15.84.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The business had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%. Analysts expect that LifeMD, Inc. will post -0.37 EPS for the current fiscal year.

LifeMD Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.